TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2211201
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (consolidation radiotherapy after induction chemotherapy)
Study: 374163
Drug: Two 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 225 mg tablets of Phyllocontin (slow-release aminophylline)
Study: 27052634
Drug: Metformin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1.5 g/day)
Study: 18056903
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus GP IIb/IIIa inhibitors (n = 4603)
Study: 18056903
Drug: Bivalirudin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin plus GP IIb/IIIa inhibitors (n = 4604)
Study: 18056903
Drug: Bivalirudin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin monotherapy (n = 4612)
Study: 18056903
Drug: Deferred use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred use of GP IIb/IIIa inhibitors
Study: 7744539
Drug: Moricizine HCl
Normalized name: moricizine HCl
DrugBank: Moricizine (DB00680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine HCl at 200 mg twice daily for 5 days
Study: 6216612
Drug: Aqueous procaine
Normalized name: Aqueous procaine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous procaine penicillin G (4.8 x 10(6) units plus 1 g of oral probenecid)
Study: 6216612
Drug: Spectinomycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin (2 g)
Study: 31990877
Drug: SMS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS group (received SMS about bowel preparation practices 3 days before colonoscopy)
Study: 18640632
Drug: Aromatherapy treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy treatment, details on dosage and duration not specified.
Study: 12816787
Drug: Commercial milk-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial milk-based cereal drink (MCD) and porridge (CC group)
Study: 6141926
Drug: 1% pindolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% pindolol eye-drops, twice daily
Study: 6141926
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol eye-drops, twice daily
Study: 30768462
Drug: Early rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early rocuronium administration (n = 58)
Study: 30768462
Drug: Late rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late rocuronium administration (n = 56)
Study: 24119983
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hemostatic treatment)
Study: 10446691
Drug: Troglitazone 200
Normalized name: troglitazone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 200 mg twice daily (group A)
Study: 7768546
Drug: Oral typhoid
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral typhoid vaccine (Ty21a)
Study: 911030
Drug: BCG adjuvant
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG adjuvant immunotherapy
Study: 23855973
Drug: 5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/d of fish oil (providing 3 g of EPA + DHA)
Study: 10743982
Drug: Intact lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intact lansoprazole capsule (regimen D)
Study: 10376262
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg midazolam
Study: 8922766
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg midazolam plus 250 micrograms alfentanil
Study: 1388952
Drug: Mechanical oral
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical oral hygiene (wooden interdental cleaner)
Study: 27433812
Drug: Gatorade and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatorade and 357 g of PEG (day-prior dose)
Study: 27433812
Drug: Split-dose bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split-dose bowel preparations (3 different types)
Study: 27433812
Drug: Split-dose bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split-dose bowel preparations
Study: 17223409
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of simvastatin
Study: 16999946
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of simvastatin
Study: 11368263
Drug: Clindamycin vaginal
Normalized name: clindamycin Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin vaginal ovules (3-day treatment)
Study: 11368263
Drug: Clindamycin vaginal
Normalized name: clindamycin Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin vaginal cream (7-day treatment)
Study: 9443537
Drug: d-amphetamine (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (5, 10 mg P.O.)
Study: 9443537
Drug: Diazepam (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (2.5, 5 mg P.O.)
Study: 9443537
Drug: Tripelennamine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripelennamine (75 mg)
Study: 7977316
Drug: nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrendipine (10 to 40 mg/d)
Study: 7977316
Drug: enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (5 to 20 mg/d)
Study: 2686418
Drug: Ciprofloxacin 200
Normalized name: ciprofloxacin 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 200 mg intravenously every 12 hours
Study: 2686418
Drug: Ceftazidime 0.5
Normalized name: avibactam-ceftazidime 0.5 g-2 g intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 0.5 to 2 g intravenously every eight to 12 hours
Study: 31705581
Drug: 10% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lidocaine spray combined with 2% lidocaine gel
Study: 31705581
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution spray combined with 2% lidocaine gel
Study: 27957618
Drug: Corticosteroid local
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid local injection
Study: 23933953
Drug: Prednisolone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 7.5 mg once daily (n = 12)
Study: 23933953
Drug: Prednisolone 30
Normalized name: prednisolone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 30 mg once daily (n = 12)
Study: 21799173
Drug: Cilostazol group
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol group (aspirin plus cilostazol)
Study: 21799173
Drug: Clopidogrel group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel group (aspirin plus clopidogrel)
Study: 15562366
Drug: Canarypox vector-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canarypox vector-based HIV vaccines (ALVAC-HIV)
Study: 12815771
Drug: Inhalation anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anaesthesia
Study: 12815771
Drug: Mixed inhalation
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed inhalation and intravenous anaesthesia
Study: 8315424
Drug: Doxorubicin 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 80 mg/m2
Study: 8315424
Drug: Ifosfamide 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 7.5 g/m2 plus Doxorubicin 60 mg/m2
Study: 8315424
Drug: Mitomycin 8
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin 8 mg/m2 plus Doxorubicin 40 mg/m2 plus Cisplatin 60 mg/m2
Study: 3554564
Drug: Thymopentin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (50 mg daily for the first two weeks, then three times weekly)
Study: 3554564
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution intravenously)
Study: 22189383
Drug: Cisplatin-based neoadjuvant
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based neoadjuvant chemotherapy (NAC)
Study: 22189383
Drug: Cisplatin-based neoadjuvant
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based neoadjuvant chemotherapy (NAC) with complete downstaging (CD)
Study: 20163382
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) combined with nicotine patches plus cognitive behavioral group counseling for smoking cessation (n = 153)
Study: 20163382
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) alone (n = 72)
Study: 8704116
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol (2 micrograms after each dialysis)
Study: 8704116
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol (2 micrograms after each dialysis)
Study: 6414795
Drug: Oral long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral long-term treatment with antiarrhythmic drugs (aprindine, mexiletine, disopyramide, amiodarone)
Study: 31919123
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of activated and expanded haploidentical NK (NKAE) cells, two doses once a week, using a GMP K562‐mbIL15‐41BBL stimulus from a haploidentical donor and interleukin 2 subcutaneously.
Study: 30575616
Drug: Office-based accommodative/vergence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based accommodative/vergence therapy (OBAVT)
Study: 29078971
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment without needle penetration
Study: 25730341
Drug: Interoceptive exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interoceptive exposure (IE) through running, following a 3-day group cognitive behavioral therapy intervention.
Study: 16518519
Drug: Oxerutins (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxerutins (2 g/day)
Study: 16518519
Drug: Daflon (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon (3 tablets of 500 mg daily for 8 weeks)
Study: 29786959
Drug: Ertugliflozin 15
Normalized name: ertugliflozin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 15 mg with Sitagliptin 100 mg
Study: 29786959
Drug: Ertugliflozin 15
Normalized name: ertugliflozin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 15 mg with Metformin 1000 mg
Study: 29786959
Drug: Ertugliflozin 15
Normalized name: ertugliflozin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 15 mg with Glimepiride 1 mg
Study: 29786959
Drug: Ertugliflozin 15
Normalized name: ertugliflozin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 15 mg with Simvastatin 40 mg
Study: 21703829
Drug: Cranberry juice,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice, twice a day for 6 weeks (including 2 weeks post-treatment)
Study: 21703829
Drug: Placebo beverage,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage, twice a day for 6 weeks (including 2 weeks post-treatment)
Study: 18037444
Drug: Transition to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transition to Community program, involving interviews by an advanced practice psychiatric nurse, communication via prepaid cellular phones, and follow-up on medication compliance and outpatient appointments.
Study: 12381235
Drug: Combined antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antiretroviral therapy in elderly patients
Study: 12381235
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment and therapy guidelines
Study: 12381235
Drug: Antiretroviral drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral drug dosage adjustment
Study: 6449902
Drug: Intravenous mezlocillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous mezlocillin, 260 mg/kg/day in six divided doses
Study: 6449902
Drug: Intravenous mezlocillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous mezlocillin, 450 mg/kg/day in six divided doses
Study: 6449902
Drug: Combined results
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined results from both dosage regimens
Study: 27693901
Drug: Stop-and-go methadone
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop-and-go methadone titration method
Study: 27693901
Drug: Progressive methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive methadone titration method
Study: 24225312
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no thermal agent)
Study: 19672115
Drug: Dead Sea
Normalized name: Cleanser Topical application Soap [MG217 DEAD SEA SOAP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dead Sea mineral-enriched body lotion (DS)
Study: 19672115
Drug: Placebo lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lotion with no Dead Sea minerals (P1)
Study: 19672115
Drug: Placebo lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lotion with no active ingredients (P2)
Study: 7530168
Drug: m‐BACOD chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: m‐BACOD chemotherapy
Study: 2225700
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg mefloquine hydrochloride
Study: 2225700
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg mefloquine hydrochloride
Study: 2225700
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg and 1500 mg mefloquine hydrochloride
Study: 31670238
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all four image contrasts (FLAIR, T1, T2, proton density)
Study: 21270194
Drug: Fasting Plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting Plasma Glucose (FPG) ≥ 126 mg/dL
Study: 16197921
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium infusion (0.1 mmol/kg)
Study: 14510997
Drug: TAC in
Normalized name: TAC Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC in Transfersome (2.5 micro g cm‐2)
Study: 14510997
Drug: TAC cream
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAC cream (25 micro g cm‐2)
Study: 14510997
Drug: TAC ointment
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAC ointment (25 micro g cm‐2)
Study: 14510997
Drug: TAC cream
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAC cream
Study: 1450797
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg and Misoprostol 200 micrograms
Study: 1450797
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg and Placebo
Study: 16230678
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin 40 mg/m2
Study: 25691677
Drug: Androgen-Deprivation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen-Deprivation Therapy plus Radiotherapy (ADT+RT)
Study: 25691677
Drug: Androgen-Deprivation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen-Deprivation Therapy alone (ADT)
Study: 21199265
Drug: colesevelam 3.75
Normalized name: colesevelam 3.75 g oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: colesevelam 3.75 g/day
Study: 9403260
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application of povidone-iodine
Study: 9403260
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application of povidone-iodine
Study: 9403260
Drug: Once or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once or twice daily application of povidone-iodine
Study: 7917797
Drug: Amoxycillin 250
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 250 mg three times daily
Study: 25738794
Drug: Initial conservative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial conservative treatment (subsequent evacuation allowed if deemed necessary)
Study: 12271281
Drug: Cryotherapy followed
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy followed by topical imiquimod and salicylic acid
Study: 9364674
Drug: S‐L* vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐L* vaccine (20 micrograms/dose)
Study: 9364674
Drug: Engerix‐B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix‐B vaccine (20 micrograms/dose)
Study: 3083705
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole and ceftriaxone
Study: 29912663
Drug: Stem cell
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cell therapy (bone marrow-derived mononuclear cells)
Study: 29912663
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy alone (control group)
Study: 27113487
Drug: Interim pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interim pressure garment (IPG) therapy (4-6 mmHg) applied post-operatively on day 5
Study: 24831251
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) plus 10 mg zolpidem nightly
Study: 21910714
Drug: 311-nm UVB
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 311-nm UVB therapy
Study: 20216207
Drug: Metoclopramide (MTC)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MTC) plus Dopamine (DA) infusion
Study: 20216207
Drug: Metoclopramide (MTC)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MTC) infusion
Study: 8314480
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b 3 MU three times weekly for three months
Study: 8314480
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b 3 MU three times weekly for six months
Study: 8314480
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b 6 MU two times weekly for six months
Study: 8314480
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b 6 MU three times weekly for six months
Study: 27721533
Drug: Chloroquine 10
Normalized name: chloroquine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 10 mg/kg on Day 1, 10 mg/kg on Day 2, and 5 mg/kg on Day 3
Study: 24990776
Drug: Vipromak added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vipromak added to treatment protocol
Study: 24990776
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment scheme
Study: 22677218
Drug: milnacipran 100
Normalized name: milnacipran 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: milnacipran 100 mg/d
Study: 27945299
Drug: Neoadjuvant chemotherapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy: docetaxel 75 mg/m² and cisplatin 75 mg/m² D1 q 3 wks x 2, followed by cisplatin 40 mg/m² weekly x 6-8 concurrent with RT (66 Gy in 2-Gy fractions)
Study: 27945299
Drug: Control arm:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm: concurrent cisplatin-RT as arm 1 without neoadjuvant chemotherapy
Study: 11986439
Drug: Apple juice
Normalized name: apple juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple juice (sorbitol 0.5 g/dL; 2.6:1 fructose-to-glucose ratio)
Study: 7267475
Drug: prenylamine 180
Normalized name: prenylamine
DrugBank: Prenylamine (DB04825)
Approvals — FDA: no, EMA: no, PMDA: no
Description: prenylamine 180 mg daily
Study: 28129756
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing and cognitive behavioural therapy based intervention for AUDs, administered over 16 sessions at 8 HIV clinics.
Study: 23843062
Drug: Oxybutynin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin treatment (Group I)
Study: 15555005
Drug: Fleet Prep
Normalized name: Fleet Prep Kit #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleet Prep Kit 3 (FPK #3) - single dose (45 ml) oral sodium phosphate (NaP), four bisacodyl tablets (5 mg), and one bisacodyl enema (10 mg)
Study: 15555005
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L polyethylene glycol solution (PEG)
Study: 11869753
Drug: Integrated, clinic-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated, clinic-based treatment delivery system emphasizing algorithm-driven somatotherapy, standardized patient education, and easy access to a primary mental health care provider.
Study: 7946230
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (one-month course including passive listening and active singing)
Study: 14671147
Drug: Cinacalcet (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (30, 40, or 50 mg)
Study: 8788290
Drug: Pancreatic supplementation
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic supplementation therapy